{"title":"Risk Factors for Myasthenic Crisis in Patients With Myasthenia Gravis: A Retrospective Study in Southwest China","authors":"Xue Lin, Hongxi Chen, Xiaofei Wang, Ziyan Shi, Rui Wang, Hongyu Zhou","doi":"10.1155/ijcp/9145129","DOIUrl":null,"url":null,"abstract":"<div>\n <p><b>Background:</b> Myasthenic crisis (MC) is a rare but potentially fatal complication that can significantly worsen the prognosis of patients with myasthenia gravis (MG). However, predicting the occurrence of MC remains challenging. Therefore, this study aimed to identify potential risk factors associated with MC.</p>\n <p><b>Methods:</b> A retrospective study was conducted using the MG Cohort Database at the West China Hospital of Sichuan University from January 2004 to August 2023. The multivariate Cox regression analysis was performed to determine the risk factors for MC.</p>\n <p><b>Results:</b> Among the 1150 patients with MG included in the final analysis, 128 (11.1%) experienced at least one episode of MC. Independent risk factors identified for MC included age (hazard ratio [HR]: 1.02, 95% confidence interval [CI]: 1.01–1.03, <i>p</i> < 0.001), quantitative MG (QMG) score (HR: 1.04, 95% CI: 1.01–1.07, <i>p</i> = 0.003), MG Foundation of America (MGFA) class at diagnosis (HR: 3.19, 95% CI: 2.38–4.28, <i>p</i> < 0.001), and the presence of thymoma (HR: 3.21, 95% CI: 2.13–4.85, <i>p</i> < 0.001). In contrast, generalized MG (<i>p</i> = 0.891) and the presence of antimuscle-specific tyrosine kinase (MuSK) antibodies (<i>p</i> = 0.107) did not significantly increase the risk of developing MC.</p>\n <p><b>Conclusion:</b> Age, disease severity as indicated by the QMG score and MGFA class at diagnosis, along with thymoma presence were identified as potential predictors for MC in patients diagnosed with MG.</p>\n </div>","PeriodicalId":13782,"journal":{"name":"International Journal of Clinical Practice","volume":"2025 1","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ijcp/9145129","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/ijcp/9145129","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Myasthenic crisis (MC) is a rare but potentially fatal complication that can significantly worsen the prognosis of patients with myasthenia gravis (MG). However, predicting the occurrence of MC remains challenging. Therefore, this study aimed to identify potential risk factors associated with MC.
Methods: A retrospective study was conducted using the MG Cohort Database at the West China Hospital of Sichuan University from January 2004 to August 2023. The multivariate Cox regression analysis was performed to determine the risk factors for MC.
Results: Among the 1150 patients with MG included in the final analysis, 128 (11.1%) experienced at least one episode of MC. Independent risk factors identified for MC included age (hazard ratio [HR]: 1.02, 95% confidence interval [CI]: 1.01–1.03, p < 0.001), quantitative MG (QMG) score (HR: 1.04, 95% CI: 1.01–1.07, p = 0.003), MG Foundation of America (MGFA) class at diagnosis (HR: 3.19, 95% CI: 2.38–4.28, p < 0.001), and the presence of thymoma (HR: 3.21, 95% CI: 2.13–4.85, p < 0.001). In contrast, generalized MG (p = 0.891) and the presence of antimuscle-specific tyrosine kinase (MuSK) antibodies (p = 0.107) did not significantly increase the risk of developing MC.
Conclusion: Age, disease severity as indicated by the QMG score and MGFA class at diagnosis, along with thymoma presence were identified as potential predictors for MC in patients diagnosed with MG.
期刊介绍：
IJCP is a general medical journal. IJCP gives special priority to work that has international appeal.
IJCP publishes:
Editorials. IJCP Editorials are commissioned. [Peer reviewed at the editor''s discretion]
Perspectives. Most IJCP Perspectives are commissioned. Example. [Peer reviewed at the editor''s discretion]
Study design and interpretation. Example. [Always peer reviewed]
Original data from clinical investigations. In particular: Primary research papers from RCTs, observational studies, epidemiological studies; pre-specified sub-analyses; pooled analyses. [Always peer reviewed]
Meta-analyses. [Always peer reviewed]
Systematic reviews. From October 2009, special priority will be given to systematic reviews. [Always peer reviewed]
Non-systematic/narrative reviews. From October 2009, reviews that are not systematic will be considered only if they include a discrete Methods section that must explicitly describe the authors'' approach. Special priority will, however, be given to systematic reviews. [Always peer reviewed]
''How to…'' papers. Example. [Always peer reviewed]
Consensus statements. [Always peer reviewed] Short reports. [Always peer reviewed]
Letters. [Peer reviewed at the editor''s discretion]
International scope
IJCP publishes work from investigators globally. Around 30% of IJCP articles list an author from the UK. Around 30% of IJCP articles list an author from the USA or Canada. Around 45% of IJCP articles list an author from a European country that is not the UK. Around 15% of articles published in IJCP list an author from a country in the Asia-Pacific region.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
